Korro's KRRO-111 shows 96% SERPINA1 editing, 95% liver Z-AAT cut; 1H 2027 filing planned

Korro Bio, Inc.

In NSG-PiZ mice, repeat-dose KRRO-111 reached 96% SERPINA1 mRNA editing, with M-AAT at 93% of circulating AAT and total AAT of 172 μM (~6-fold vs vehicle) at Day 57.
In immunocompetent C57BL/6-PiZ mice, KRRO-111 reduced whole-liver Z-AAT by 95% versus vehicle at Day 57, measured by LC-MS/MS.
Single-dose C57BL/6-PiZ: up to 91% editing and M-AAT up to 88% of total AAT, detectable through Day 42; EC50 ~1 nM, up to 98% editing in mouse and human hepatocytes.
KRRO-111 is a subcutaneous GalNAc-conjugated oligonucleotide using ADAR to correct the pathogenic SERPINA1 transcript; Korro expects a regulatory submission in 1H 2027.
CSO Loïc Vincent said the dual profile restores functional M-AAT while cutting toxic Z-AAT; CEO Ram Aiyar said Korro plans to advance KRRO-111 into the clinic in 1H 2027.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.